{"id":500,"date":"2026-01-26T14:41:47","date_gmt":"2026-01-26T13:41:47","guid":{"rendered":"https:\/\/ced-studienzentrum.berlin\/2026\/01\/26\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/"},"modified":"2026-02-03T11:03:09","modified_gmt":"2026-02-03T10:03:09","slug":"ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab","status":"publish","type":"post","link":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","title":{"rendered":"Ulcerative colitis: Study on the efficacy and safety of risankizumab"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Listings&#8221; module_id=&#8221;target group&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; background_enable_image=&#8221;off&#8221; background_size=&#8221;custom&#8221; background_image_width=&#8221;90%&#8221; background_position=&#8221;bottom_right&#8221; top_divider_height=&#8221;51px&#8221; locked=&#8221;off&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;3&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|auto|-1px|auto|false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_post_title meta=&#8221;off&#8221; featured_image=&#8221;off&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#10344C&#8221; title_font_size=&#8221;45px&#8221; custom_margin=&#8221;||15px|||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_post_title][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;1f09816e-184e-4ce5-a4cf-b39c52c423ca&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#10344C&#8221; text_font_size=&#8221;20px&#8221; text_line_height=&#8221;1.8em&#8221; ul_line_height=&#8221;1.8em&#8221; custom_margin=&#8221;||||false|false&#8221; hover_enabled=&#8221;0&#8243; text_font_size_tablet=&#8221;15px&#8221; text_font_size_phone=&#8221;14px&#8221; text_font_size_last_edited=&#8221;on|phone&#8221; header_font_size_tablet=&#8221;55px&#8221; header_font_size_last_edited=&#8221;off|desktop&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><strong>ClinicalTrials.gov ID:<\/strong> NCT03398135<br \/><strong>Sponsor:<\/strong> AbbVie Information provided by: AbbVie (responsible party)<\/p>\n<p><strong>Official title:<\/strong><br \/>Multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension to evaluate the efficacy and safety of risankizumab in patients with ulcerative colitis.<\/p>\n<p><strong>Study overview:<\/strong><br \/>The aim is to evaluate the safety and efficacy of risankizumab in patients with ulcerative colitis who have responded to induction therapy with risankizumab in a previous AbbVie study.<\/p>\n<p>The study consists of three sub-studies and a continuous treatment extension (CTE):<\/p>\n<ul>\n<li>Sub-study 1: 52-week, randomized, double-blind, placebo-controlled maintenance study<\/li>\n<li>Sub-study 2: 52-week, randomized, exploratory maintenance study<\/li>\n<li>Sub-study 3: Open-label long-term extension study for participants who have completed sub-study 1 or 2 or who have responded to induction therapy in study M16-067 but were unable to receive a final endoscopy due to COVID-19 or geopolitical conflicts (Ukraine and affected regions)<\/li>\n<\/ul>\n<p>The CTE serves to ensure continuous treatment with risankizumab until the drug is commercially available or can be obtained locally.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ClinicalTrials.gov ID: NCT03398135Sponsor: AbbVie Information provided by: AbbVie (responsible party) Official title:Multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension to evaluate the efficacy and safety of risankizumab in patients with ulcerative colitis. Study overview:The aim is to evaluate the safety and efficacy of risankizumab in patients with ulcerative colitis who have responded [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[37,36],"tags":[],"class_list":["post-500","post","type-post","status-publish","format-standard","hentry","category-active-recruitment-completed","category-for-study-partners"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst\" \/>\n<meta property=\"og:description\" content=\"ClinicalTrials.gov ID: NCT03398135Sponsor: AbbVie Information provided by: AbbVie (responsible party) Official title:Multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension to evaluate the efficacy and safety of risankizumab in patients with ulcerative colitis. Study overview:The aim is to evaluate the safety and efficacy of risankizumab in patients with ulcerative colitis who have responded [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"CED Studienzentrum Karlshorst\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:41:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T10:03:09+00:00\" \/>\n<meta name=\"author\" content=\"Pauline Lauterbach\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pauline Lauterbach\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/\"},\"author\":{\"name\":\"Pauline Lauterbach\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"headline\":\"Ulcerative colitis: Study on the efficacy and safety of risankizumab\",\"datePublished\":\"2026-01-26T13:41:47+00:00\",\"dateModified\":\"2026-02-03T10:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/\"},\"wordCount\":375,\"articleSection\":[\"Active, recruitment completed\",\"For study partners\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/\",\"url\":\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/\",\"name\":\"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst\",\"isPartOf\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#website\"},\"datePublished\":\"2026-01-26T13:41:47+00:00\",\"dateModified\":\"2026-02-03T10:03:09+00:00\",\"author\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"breadcrumb\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/ced-studienzentrum.berlin\/en\/ced-study-center-karlshorst\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ulcerative colitis: Study on the efficacy and safety of risankizumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#website\",\"url\":\"https:\/\/ced-studienzentrum.berlin\/en\/\",\"name\":\"CED Studienzentrum Karlshorst\",\"description\":\"Dr. Thomas Brunk\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ced-studienzentrum.berlin\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb\",\"name\":\"Pauline Lauterbach\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"caption\":\"Pauline Lauterbach\"},\"url\":\"https:\/\/ced-studienzentrum.berlin\/en\/author\/paulilauterbachnutzer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","og_locale":"en_US","og_type":"article","og_title":"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst","og_description":"ClinicalTrials.gov ID: NCT03398135Sponsor: AbbVie Information provided by: AbbVie (responsible party) Official title:Multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension to evaluate the efficacy and safety of risankizumab in patients with ulcerative colitis. Study overview:The aim is to evaluate the safety and efficacy of risankizumab in patients with ulcerative colitis who have responded [&hellip;]","og_url":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","og_site_name":"CED Studienzentrum Karlshorst","article_published_time":"2026-01-26T13:41:47+00:00","article_modified_time":"2026-02-03T10:03:09+00:00","author":"Pauline Lauterbach","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pauline Lauterbach","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/#article","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/"},"author":{"name":"Pauline Lauterbach","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"headline":"Ulcerative colitis: Study on the efficacy and safety of risankizumab","datePublished":"2026-01-26T13:41:47+00:00","dateModified":"2026-02-03T10:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/"},"wordCount":375,"articleSection":["Active, recruitment completed","For study partners"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","url":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","name":"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website"},"datePublished":"2026-01-26T13:41:47+00:00","dateModified":"2026-02-03T10:03:09+00:00","author":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"breadcrumb":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/ced-studienzentrum.berlin\/en\/ced-study-center-karlshorst\/"},{"@type":"ListItem","position":2,"name":"Ulcerative colitis: Study on the efficacy and safety of risankizumab"}]},{"@type":"WebSite","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website","url":"https:\/\/ced-studienzentrum.berlin\/en\/","name":"CED Studienzentrum Karlshorst","description":"Dr. Thomas Brunk","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ced-studienzentrum.berlin\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb","name":"Pauline Lauterbach","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","caption":"Pauline Lauterbach"},"url":"https:\/\/ced-studienzentrum.berlin\/en\/author\/paulilauterbachnutzer\/"}]}},"_links":{"self":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/comments?post=500"}],"version-history":[{"count":3,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/500\/revisions"}],"predecessor-version":[{"id":503,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/500\/revisions\/503"}],"wp:attachment":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/media?parent=500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/categories?post=500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/tags?post=500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}